Drug Profile
Research programme: receptor tyrosine kinase inhibitors - GlaxoSmithKline
Alternative Names: REarranged in Transfection tyrosine kinase inhibitors; GSK 1838705A; GW-578257A; RET inhibitors; RET tyrosine kinase inhibitors; VEGFR-2/TIE-2 inhibitors - GSKLatest Information Update: 18 Apr 2011
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Benzimidazoles; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Insulin-like growth factor-I receptor antagonists; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer